Lantern Pharma Inc. (Nasdaq: LTRN) said it plans to launch a clinical trial in early 2026 for a rare pediatric brain cancer, following what it called an “optimistic meeting” with the U.S. Food and Drug Administration. In a statement, CEO, Panna Sharma said, “This guidance not only reinforces our trial design but also highlights the potential of our AI platform, RADR, in identifying and optimizing combination regimens like spironolactone for these devastating pediatric CNS cancers.”
The Dallas-based biotech announced the planned Phase 1b/2 trial will evaluate its drug candidate LP-184/STAR-001 in children with central nervous system cancers, including atypical teratoid rhabdoid tumors—a fast-growing brain tumor that primarily affects young children.
Lantern uses artificial intelligence to identify biomarkers and potential treatment combinations across a range of cancers. Its RADR platform analyzes large genomic datasets to surface genetic variations linked to specific cancers, with the goal of accelerating oncology drug development. Go to Dallas Innovates for the full story.
